| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 2,484 | - | ||
| Restricted cash | 60 | 60 | ||
| Prepaid expenses | 349 | 447 | ||
| Other current assets | 53 | 83 | ||
| Cash | - | 2,711 | ||
| Total current assets | 2,946 | 3,301 | ||
| Goodwill | 8,430 | 8,430 | ||
| Other intangible assets | 34,000 | 39,180 | ||
| Total assets | 45,376 | 50,911 | ||
| Accounts payable | 10,844 | 11,607 | ||
| Accrued expenses | 1,623 | 2,468 | ||
| Convertible notes, net | 663 | 700 | ||
| Notes payable, net | 198 | 179 | ||
| Notes payable - related party, net | 1,256 | 668 | ||
| Warrant liabilities | 503 | 866 | ||
| Convertible notes, related party | - | 0 | ||
| Other current liabilities | 481 | 650 | ||
| Total current liabilities | 15,568 | 17,138 | ||
| Derivative liability | 100 | - | ||
| Other non-current liabilities | 69 | 128 | ||
| Deferred tax liability | 6,952 | 8,040 | ||
| Total liabilities | 22,689 | 25,306 | ||
| Authorized 330,854,276,210 and 245,035,791,523 ordinary shares at september 30, 2025 and december 31, 2024, respectively issued and outstanding 65,229,461,523 and 53,186,919,523 ordinary shares at september 30, 2025 and december 31, 2024, respectively | 6,523 | 6,523 | ||
| Additional paid-in capital | 224,366 | 220,846 | ||
| Capital redemption reserve | 52,194 | 52,194 | ||
| Accumulated other comprehensive loss | -1,144 | -1,106 | ||
| Accumulated deficit | -259,252 | -252,852 | ||
| Total shareholders equity | 22,687 | 25,605 | ||
| Total liabilities and shareholders equity | 45,376 | 50,911 | ||
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)